Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis

Background The Immunoscore method, based on the distribution of the quantification of cytotoxic and memory T cells, provides an indicator of tumor recurrence for colon cancer. However, recent evidence has suggested that immune checkpoint expression represents a surrogate measure of tumor-infiltrating T cell exhaustion, and therefore may serve as a more accurate prognostic biomarker for colon cancer. Indoleamine 2, 3-dioxygenase 1 (IDO1), a potent immunosuppressive molecule, has been strongly associated with T-cell infiltration, but it lacks universal prognostic significance among all of the cancer subtypes. Our aim was to elucidate the prognostic significance of the combination of IDO1 and CD8A expression in colon cancer. Methods Gene expression and clinical survival data were analyzed using The Cancer Genome Atlas (TCGA) data set and validated using NCBI Gene Expression Omnibus (NCBI-GEO) cohort. Hierarchical clustering, functional enrichment analyses, and immune infiltration analysis were applied to evaluate the distinctive immune statuses in colon cancer risk subgroups stratified by IDO1 and CD8A expression. Moreover, Multivariate Cox regression analysis and Receiver Operating Characteristic (ROC) analyses were conducted to determine the prognostic value of IDO1/CD8A stratification. The IDO1/CD8A classifier may be suitable for use in the prediction of cancer development. It was validated via an in vivo murine model. Results The stratification analysis demonstrated that the colon cancer subtype with the CD8AhighIDO1high* tumor resulted in the worst survival despite high levels of CD8 infiltrates. Its poor prognosis was associated with high levels of immune response, checkpoint genes, and Th1/IFN-γ gene signatures, regardless of CMS classification. Moreover, the IDO1/CD8A stratification was identified as an independent prognostic factor of overall survival (OS) and a useful predictive biomarker in colon cancer. In vivo data revealed the CD8AhighIDO1high group showed strong correlations with late-stage metastasis of colon carcinoma cells and upregulation of immune checkpoints. Conclusions The findings indicate that the proposed IDO1/CD8A stratification has exact and independent prognostic implications beyond CD8 T cell alone and CMS classification. As a result, it may represent a promising tool for risk stratification in colon cancer and improve the development of immunotherapies for patients with colon cancer in the future.

[1]  R. C. Macridis.  A review , 1963 .

[2]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[3]  James W. C. White.  Environmental Studies at the University of Colorado , 1995 .

[4]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[6]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[7]  Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression , 2009 .

[8]  G. Visner,et al.  Reduced Cytotoxic Function of Effector CD8+ T Cells Is Responsible for Indoleamine 2,3-Dioxygenase-Dependent Immune Suppression1 , 2009, The Journal of Immunology.

[9]  Antonio Polley,et al.  Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection , 2009, Nature Immunology.

[10]  F. Marincola,et al.  The immune score as a new possible approach for the classification of cancer , 2012, Journal of Translational Medicine.

[11]  D. Munn,et al.  Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. , 2011, Blood.

[12]  G. Dranoff,et al.  Cancer immunology—analysis of host and tumor factors for personalized medicine , 2011, Nature Reviews Clinical Oncology.

[13]  C. Decaestecker,et al.  Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer , 2011, British Journal of Cancer.

[14]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[15]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[16]  Kimberly R. Jordan,et al.  Influence of human immune cells on cancer: studies at the University of Colorado , 2012, Immunologic Research.

[17]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[18]  J. Shao,et al.  Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization , 2014, Molecular Cancer.

[19]  J. Galon,et al.  From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.

[20]  J. Shao,et al.  Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization , 2014, Cell Death and Differentiation.

[21]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[22]  Jeffrey T. Leek,et al.  Preserving biological heterogeneity with a permuted surrogate variable analysis for genomics batch correction , 2014, Bioinform..

[23]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[24]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[25]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[26]  M. Koch,et al.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. , 2015, The Journal of clinical investigation.

[27]  J. Liu,et al.  ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis , 2015, Cell Death and Disease.

[28]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[29]  W. Cooper,et al.  The Role of Tumor‐Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non–Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Beicheng Sun,et al.  The pros and cons of dying tumour cells in adaptive immune responses , 2017, Nature Reviews Immunology.

[31]  A. Whittemore,et al.  Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer , 2017, JAMA oncology.

[32]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[33]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[34]  J. Wargo,et al.  Hallmarks of response to immune checkpoint blockade , 2017, British Journal of Cancer.

[35]  J. Guinney,et al.  Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer , 2017, Nature Reviews Cancer.

[36]  K. Jirström,et al.  The clinical impact of tumour‐infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study , 2017, International journal of cancer.

[37]  Fangxuan Li,et al.  IDO1: An important immunotherapy target in cancer treatment , 2017, International immunopharmacology.

[38]  A. Senagore,et al.  Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications. , 2017, International biological and biomedical journal.

[39]  Jun S. Liu,et al.  TIMER : AWeb Server for Comprehensive Analysis of Tumor-In fi ltrating Immune Cells , 2017 .

[40]  C. James,et al.  Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival , 2017, Clinical Cancer Research.

[41]  Yun Wang,et al.  The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases , 2018, Cancer Immunology, Immunotherapy.

[42]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[43]  T. Schumacher,et al.  T Cell Dysfunction in Cancer. , 2018, Cancer cell.

[44]  P. Ulivi,et al.  Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine? , 2018, International journal of molecular sciences.

[45]  D. Tougeron,et al.  Results and challenges of immune checkpoint inhibitors in colorectal cancer , 2018, Expert opinion on biological therapy.

[46]  E. Jaffee,et al.  Emerging strategies for combination checkpoint modulators in cancer immunotherapy , 2018, The Journal of clinical investigation.

[47]  P. Laurent-Puig,et al.  The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors , 2018, Journal of the National Cancer Institute.

[48]  W. Tian,et al.  Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells , 2018, Journal of Medical Genetics.

[49]  D. Wainwright,et al.  IDO1 in cancer: a Gemini of immune checkpoints , 2018, Cellular & Molecular Immunology.

[50]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[51]  Xu Wang,et al.  Targeting the IDO1 pathway in cancer: from bench to bedside , 2018, Journal of Hematology & Oncology.

[52]  Leonard D. Goldstein,et al.  An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. , 2018, Cancer discovery.

[53]  A. Debucquoy,et al.  The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. , 2018, Cancer cell.

[54]  Jian Yu,et al.  Colorectal cancer prevention: Immune modulation taking the stage. , 2018, Biochimica et biophysica acta. Reviews on cancer.

[55]  M. Fakih,et al.  Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. , 2019, The Journal of clinical investigation.

[56]  R. Schreiber,et al.  Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. , 2019, Cold Spring Harbor perspectives in biology.

[57]  Ludmila V. Danilova,et al.  Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival , 2019, Cancer Immunology Research.

[58]  M. Najafi,et al.  CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review , 2018, Journal of cellular physiology.

[59]  Beibei Ru,et al.  TISIDB: an integrated repository portal for tumor-immune system interactions , 2019, Bioinform..

[60]  F. Ciardiello,et al.  Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. , 2019, Cancer treatment reviews.

[61]  Sam Q. Sun,et al.  Dynamic host immune response in virus-associated cancers. , 2019 .

[62]  A. Rosenwald,et al.  Prognostic value of tumour-infiltrating CD8+ lymphocytes in rectal cancer after neoadjuvant chemoradiation: is indoleamine-2,3-dioxygenase (IDO1) a friend or foe? , 2019, Cancer Immunology, Immunotherapy.

[63]  F. Tanaka,et al.  Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer , 2019, British Journal of Cancer.

[64]  Liang Guo,et al.  Colorectal Cancer Immune Infiltrates: Significance in Patient Prognosis and Immunotherapeutic Efficacy , 2020, Frontiers in Immunology.

[65]  P. Parikh,et al.  Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer , 2020, Cancer Immunology Research.

[66]  T. Mohr,et al.  IDO1+ Paneth cells promote immune escape of colorectal cancer , 2020, Communications Biology.